A MULTIFACETED DIGITAL HEALTH PLATFORM TO ADVANCE ALZHEIMER'S DISEASE PATIENT MONITORING, SAFETY, CARE, AND RESEARCH.

一个多层面的数字健康平台，可推进阿尔茨海默病患者的监测、安全、护理和研究。

• 批准号: 10325493
• 负责人: Jon Andrew Corkey
• 金额: $ 49.58万
• 依托单位: AMISSA, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10325493
• 关键词: Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; American; Americas; Anxiety; Appointment; Architecture; Artificial Intelligence; Authorization documentation; Behavior; Behavioral; Biological Markers; Biometry; Caregiver Burden; Caregivers; Caring; Cellular Phone; Clinical Trials; Collection; Computer software; Dangerousness; Data; Data Collection; Databases; Decentralization; Dementia; Dementia caregivers; Detection; Devices; Disease; Disease Progression; Early Diagnosis; Elderly; Emergency Situation; Environment; Exhibits; Family; Feedback; Feeling; Fees; Frequencies; Future; Goals; Health; Health Insurance Portability and Accountability Act; Health behavior; Heart Rate; Home; Hour; Individual; Intervention; Intervention Studies; Interview; Knowledge; Life; Location; Longevity; Longitudinal trends; Measures; Medical Research; Mind; Minority Groups; Modeling; Monitor; Notification; Onset of illness; Outcome; Parents; Patient Care; Patient Monitoring; Patient Recruitments; Patient Self-Report; Patient Transfer; Patients; Pattern; Performance; Personal Computers; Personal Satisfaction; Persons; Phase; Phenotype; Physical Exercise; Physicians; Population; Population Heterogeneity; Preventive treatment; Process; Public Health; Quality of life; Research; Research Personnel; Research Support; Resources; Rural Population; S Phase; Safety; Sampling; Scientist; Secure; Shame; Small Business Innovation Research Grant; Stigmatization; Stress; Symptoms; Techniques; Technology; Testing; Time; Travel; United States National Institutes of Health; Universities; Visual; base; caregiving; clinically relevant; cloud based; community based evaluation; cost; dashboard; data exchange; design; digital; digital health; experience; falls; handheld mobile device; humiliation; improved; insight; lifestyle intervention; loved ones; meetings; mobile application; modifiable behavior; multimodal data; novel; patient safety; peace; prevent; prototype; racial minority; recruit; remote monitoring; remote patient monitoring; rural underserved; sedentary lifestyle; sensor; sleep behavior; smart watch; social; social stigma; socialization behavior; tool; volunteer

Project Summary Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) are projected to affect 50 million Americans by 2050. In 2019, more than 16 million Americans struggled while providing unpaid care for people with AD/ADRD and they need stigma-free solutions to help remotely monitor challenging AD/ADRD behaviors like falling and wandering. Separate but related, many AD/ADRD clinical trials are siloed and require patient volunteers and their caregivers to travel to in-person appointments. This is burdensome for families, increases the cost to conduct studies, and data collected is often non-representative of daily life. Amissa Inc. has developed a stigma- free, prototype solution to significantly advance AD/ADRD patient monitoring, safety, and caregiving while simultaneously aggregating high-frequency digital biomarkers to advance medical research. Several competitors have developed hardware devices for tracking elderly individuals who wander and/or fall however, AD/ADRD patients express feelings of stress, anxiety, humiliation, burden, and stigma associated with dementia when wearing these “special” devices. AD/ADRD caregivers seek “socially-acceptable” devices that improve health and location monitoring, provide peace of mind, reduce worry, improve patient safety and quality of life without loved ones feeling shame or embarrassment. Amissa’s prototype software application, created for widely available, consumer-grade smartwatches, enables families to remotely monitor when loved ones fall inside or outside the home and help prevent dangerous wandering episodes. Our initial software application also sends emergency push notifications to key stakeholders when loved ones exhibit uncommon behaviors (e.g. sudden change in variable heart rate). This Phase I SBIR proposal is designed to develop a platform which passively and unobtrusively collects time-based behavioral and biometric data from AD/ADRD patient smartwatches in real-life settings to improve caregiving while also establishing a high-frequency cloud database where one does not currently exist for AD/ADRD research. Aim 1 will develop a caregiver-designed AD/ADRD patient monitoring application for off-the-shelf consumer smartwatches and conduct user-experience and user-interface testing to facilitate feedback for iterative product design improvement. Utilizing opt-in user data from Amissa’s caregiver monitoring application, Aim 2 will establish a novel high-frequency behavioral and biometric cloud database to advance AD/ADRD digital biomarker research capabilities to predict patient falls an wandering. Amissa’s project intends to enable faster collection of multimodal data via broader demographic populations to advance AD/ADRD medical research. This Phase I SBIR has the potential for high impact by providing a single, low-cost, digital technology solution to improve AD/ADRD patient care and safety while reducing stress for caregivers and families. Furthermore, this research will improve capabilities and reduce costs of conducting decentralized clinical trials in real-life environments. At scale, our goal is to advance the forecasting of symptom trajectories and enable physicians to suggest personalized preventative treatments to delay onset or prevent AD/ADRD.

项目概要 阿尔茨海默病 (AD) 和 AD 相关痴呆症 (ADRD) 预计将影响 5000 万美国人 2050年。2019年，超过1600万美国人在为 AD/ADRD 患者提供无偿护理的过程中陷入困境 他们需要无耻辱的解决方案来帮助远程监控具有挑战性的 AD/ADRD 行为，例如跌倒和 许多 AD/ADRD 临床试验是独立但相关的，需要患者志愿者和志愿者。 他们的护理人员亲自前往预约，这对家庭来说是负担，增加了成本。 进行研究，并且收集的数据通常不代表日常生活。 免费的原型解决方案，可显着推进 AD/ADRD 患者监测、安全和护理，同时 同时聚合高频数字生物标记以推进医学研究。 已经开发出用于跟踪徘徊和/或跌倒的老年人的硬件设备，但是，AD/ADRD 当患者表达与痴呆相关的压力、焦虑、羞辱、负担和耻辱感时 佩戴这些“特殊”设备的 AD/ADRD 护理人员寻求能够改善健康的“社会可接受的”设备。 和位置监控，让您安心、减少担忧，提高患者安全和生活质量，无需担心。 Amissa 的原型软件应用程序为广泛创建，让亲人感到羞耻或尴尬。 可用的消费级智能手表使家庭能够远程监控亲人何时跌倒或跌倒 我们最初的软件应用程序还发送信息，帮助防止危险的流浪事件。 当亲人表现出不常见的行为（例如突然 第一阶段 SBIR 提案旨在开发一个被动的平台。 并从 AD/ADRD 患者智能手表中悄悄收集基于时间的行为和生物识别数据 现实生活中的环境，以改善护理，同时还建立一个高频云数据库 目前尚不存在 AD/ADRD 研究 目标 1 将开发一种由护理人员设计的 AD/ADRD 患者监测系统。 应用程序用于现成的消费者智能手表，并进行用户体验和用户界面测试 利用 Amissa 护理人员的选择加入用户数据，促进迭代产品设计改进的反馈。 监控应用程序，Aim 2将建立一个新颖的高频行为和生物识别云数据库，以 AD/ADRD 生物标记物提高了数字研究能力，可预测患者跌倒或徘徊。 旨在通过更广泛的人口统计人群更快地收集多模式数据，以推进 AD/ADRD 第一阶段 SBIR 通过提供单一、低成本、数字化的研究具有巨大影响力的潜力。 技术解决方案可改善 AD/ADRD 患者护理和安全，同时减轻护理人员和患者的压力 此外，这项研究将提高分散化的能力并降低成本。 在现实环境中进行大规模临床试验，我们的目标是推进症状轨迹的预测。 并使医生能够建议个性化的预防性治疗，以延迟发病或预防 AD/ADRD。